A new report, written jointly by the NHiS Commissioning Excellence and the Multiple Sclerosis (MS) Trust, highlights the healthcare costs of emergency hospitalization of MS patients in the United Kingdom and points to more cost-effective and better ways to care for this patient population. The executive summary and full report are…
ForuMS is a new interactive and online “journal club” where clinicians treating multiple sclerosis (MS) patients or involved in research can discuss and analyze recent papers from top peer-reviewed journals covering the latest advances in disease diagnosis and management. The educational platform, sponsored by grants from Genzyme, Mallinckrodt Pharmaceuticals, and Medtronic, uses…
MyTomorrows, a company that provides information and facilitates requests regarding clinical trials, diagnostic tests and medicines through its internet-based platform, and Hemispherx Biopharma, Inc, a pharmaceutical company specialized in the development of new therapies for life-threatening disorders, have partnered in an effort to make Hemispherx’s natural alpha interferon therapy…
Biogen Inc. recently reported that the Phase 3 ASCEND clinical trial study testing TYSABRI efficacy in patients with secondary progressive multiple sclerosis (SPMS) did not achieve its primary and secondary goals. According to the company, the comprehensive results of the study will be revealed at a future medical conference.
Researchers from the Gladstone Institutes have shown in a new study that fibrinogen, an important blood coagulation protein, can induce an autoimmune response in the central nervous system when the blood-brain barrier (BBB) is disrupted and blood proteins enter the brain. The study, entitled “Blood coagulation protein fibrinogen promotes…
Lead scientists representing Biogen and AbbVie presented new data on clinical results from the Phase 3 study DECIDE on the compound ZINBRYTA TM at the 31st Congress of the European Committee for Treatment and Research in MS (ECTRIMS) in Barcelona, Spain. The full results of the 2 to 3-year long…
Get regular updates to your inbox.